Reata Pharmaceuticals Inc (NASDAQ:RETA)
| 27.89 Delayed Data As of 4:00pm ET |  +0.29 / +1.05%Today’s Change | 25.02 Today|||52-Week Range 153.41 | +5.76% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.0B |
Company Description
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.
Contact Information
Reata Pharmaceuticals, Inc. 5320 Legacy Drive Plano Texas 75024 |
Employees
Shareholders
| Mutual fund holders | 54.95% |
| Other institutional | 28.39% |
| Individual stakeholders | 23.84% |
Top Executives
| J. Warren Huff | Chairman, President & Chief Executive Officer |
| Manmeet Singh Soni | Executive VP, Chief Operating & Financial Officer |
| W. Christian Wigley | Chief Scientific Officer, SVP & Founding Scientist |
| Colin J. Meyer | Chief Research & Development Officer, Executive VP |
| Edmund Doherty | Vice President-Medical Affairs |
